

# Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

**f** [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=210660&APPL\\_TYPE=N\)](HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=210660&APPL_TYPE=N)

**t** [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=210660&APPL\\_TYPE=N\)](HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=210660&APPL_TYPE=N)



**e** [EMAIL \(MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT\\_INFO.CFM?PRODUCT\\_NO=001&APPL\\_NO=210660&APPL\\_TYPE=N\)](MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=210660&APPL_TYPE=N)

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

## Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

## Patent and Exclusivity for: N210660

Product 001  
CYSTEINE HYDROCHLORIDE (ELCYS) SOLUTION 500MG/10ML (50MG/ML)

### Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	10478453	01/15/2039		DP	U-2752		11/19/2019

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	10583155	01/15/2039		DP	U-2752		03/10/2020

**Exclusivity Data**

Product No	Exclusivity Code	Exclusivity Expiration
Your search did not return any results		

[View a list of all patent use codes \(results\\_patent.cfm\)](#)

[View a list of all exclusivity codes \(results\\_exclusivity.cfm\)](#)

# Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS\\_PRODUCT.CFM?APPL\\_TYPE=N&APPL\\_NO=210660#36321\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?appl_type=N&appl_no=210660#36321)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS\\_PRODUCT.CFM?APPL\\_TYPE=N&APPL\\_NO=210660#36321\)](https://twitter.com/intent/tweet?text=Orange%20Book%3A%20Approved%20Drug%20Products%20with%20Therapeutic%20Equivalence%20Evaluations&url=https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?appl_type=N&appl_no=210660#36321)



 [EMAIL \(MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS\\_PRODUCT.CFM?APPL\\_TYPE=N&APPL\\_NO=210660#36321\)](mailto:?subject=Orange%20Book%3A%20Approved%20Drug%20Products%20with%20Therapeutic%20Equivalence%20Evaluations&body=https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?appl_type=N&appl_no=210660#36321)

[Home \(index.cfm?resetfields=1\)](#) | [Back to Search Results](#)

## Product Details for NDA 210660

ELCYS (CYSTEINE HYDROCHLORIDE)  
500MG/10ML (50MG/ML)  
Marketing Status: Prescription

**Active Ingredient:** CYSTEINE HYDROCHLORIDE  
**Proprietary Name:** ELCYS  
**Dosage Form; Route of Administration:** SOLUTION; INTRAVENOUS  
**Strength:** 500MG/10ML (50MG/ML)  
**Reference Listed Drug:** Yes  
**Reference Standard:** Yes  
**TE Code:**  
**Application Number:** N210660  
**Product Number:** 001  
**Approval Date:** Apr 16, 2019  
**Applicant Holder Full Name:** EXELA PHARMA SCIENCES LLC  
**Marketing Status:** Prescription  
**Patent and Exclusivity Information ([patent info.cfm?Product\\_No=001&Appl\\_No=210660&Appl\\_type=N](#))**